Relacorilant
Chemical compound
From Wikipedia, the free encyclopedia
Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.[1] Relacorilant is a glucocorticoid receptor antagonist.[1]
| |
| Clinical data | |
|---|---|
| Trade names | Lifyorli |
| Other names | CORT-125134 |
| AHFS/Drugs.com | lifyorli |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Antiglucocorticoid |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C27H22F4N6O3S |
| Molar mass | 586.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]
Relacorilant was approved for medical use in the United States in March 2026.[2][3]
Medical uses
Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.[1]
Adverse effects
The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.[2] The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]
History
Efficacy was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.[2] Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required.[2] The trial excluded participants who required chronic or frequent use of glucocorticoids.[2] Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.[2]
